Q3 2021 Investor Relations Results

Financial review Conclusion Appendix Participants Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Our pipeline projects at a glance Oncology Pharmaceuticals Cardiovascular, Renal, Metabolism References Innovation: Clinical trials Phase 1/2 Phase 3 Registration Total 45 27 6 78 55 26 4 85 5 7 1 13 26 26 9 2 37 4 5 0 9 5 1 1 7 8 3 0 11 7 1 0 8 0 2 0 2 Total 100 55 10 165 Immunology, Hepatology, Dermatology Neuroscience Ophthalmology Respiratory & Allergy Global Health Biosimilars 51 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation